Fig. 1

Proportion of PsA Patients With Axial Involvement Defined by Investigator Judgement Alone or Investigator Judgement and PRO-Based Criteria. ^aSub-groups shown include the following treatments from SELECT-PsA 1: placebo, adalimumab, and upadacitinib 15 mg; upadacitinib 30 mg is excluded. ^bSub-groups shown include the following treatments from SELECT-PsA 2: placebo and upadacitinib 15 mg; upadacitinib 30 mg is excluded. ADA, adalimumab; bDMARD, biologic disease-modifying antirheumatic drug; IR, inadequate response; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; UPA, upadacitinib